Could a cell shot free CML patients from daily pills?
NCT ID NCT07651878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a cell therapy called vididencel in 24 adults with chronic myeloid leukemia (CML) who still have traces of cancer despite taking standard medication. The goal is to see if adding vididencel to their current treatment is safe and might eventually allow them to lower or stop their daily pills. Participants receive injections over several months and are followed for up to 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vididencel (a cell therapy made from donor cells)
What this could lead to
If it works, this could help some CML patients reduce or stop their daily TKI medication without the cancer returning.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so it may not work or could have side effects. Participants may not benefit directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CML (CHRONIC MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Haukeland University Hospital
RECRUITINGBergen, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••